Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration ...

The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (CT03767348) trial in advanced melanoma was not ...

Fingal County Council has declared a planning application by the National Transport Authority for a ‘strategic’ park-and-ride ...

A Republican's call to revoke New York mayoral candidate Zohran Mamdani's citizenship has raised fears about Donald Trump's ...

Candidates are advised to apply well before the deadline and carefully follow all application instructions, as incomplete or ...

Replimune, which was seeking approval of RP1 in combination with Bristol Myers Squibb's Opdivo for the treatment of advanced melanoma, on Tuesday said the FDA issued a so-called complete response ...

Shares fell 75% to $3.04, putting the stock on track for a record closing low, according to Dow Jones Market Data. The stock ...

Purple Biotech Ltd. ('Purple Biotech' or 'the Company') (NASDAQ/TASE: PPBT), a clinical-stage company developing ...

In 2022, the DWP discovered several State Pension cases where it seemed that historical periods of Home Responsibilities ...

Lenders assess your loan application based on two main things: your financial profile and your ability to repay the borrowed ...

In line with the REIT listing, the company has entered into letter agreements with Lian Beng-Centurion, Centurion Asset ...

Replimune (REPL) announced that the U.S. Food and Drug Administration, FDA, has issued a Complete Response Letter, CRL, regarding the Biologics ...